Skip to main content
. 2022 Mar 11;51:102282. doi: 10.1016/j.redox.2022.102282

Fig. 4.

Fig. 4

PRMT5 inhibition or knockdown reduces ATF4 protein levels. a) PRMT5 inhibitor LLY283 (100 nM) effectively reduces SmBB′ symmetric arginine dimethylation and ATF4 protein levels while it increases the p53 protein levels in OCI-AML-20 cells. b) ATF4 and its target PSAT1 protein levels were downregulated in response to 3 and 6 days LLY283 (100 nM) treatment, quantitation is presented in the graph below, N = 3, mean ± SD, *p < 0.05 relative to the matched respective control. c) PRMT5 knockdown also downregulates the protein levels of ATF4, quantitation relative to control is presented in the graph below, N = 3, *p < 0.05, mean ± SD. d) PRMT5 overexpression increased ATF4 protein levels. EVI1-high TF1 and UCSD-AML-1 leukemia cells were transduced with doxycycline (dox) inducible PRMT5, followed by PRMT5 and ATF4 protein levels assessment, two days after induction, quantitation is below; N = 3, mean ± SD, *p < 0.05 relative to the matched respective control.